StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NUTX$128.02-0.84%
Fair $128.02+0.0%

NUTX

Nutex Health Inc.

Healthcare / Medical Care FacilitiesNasdaqCM

$128.02

-1.09 (-0.84%)

Fairly Valued+0.0%Fair Value $128.02Fund rank 27/100 · Data gapFallback financials|
SA 58/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 25%

FCF escenarios

weak_data · normalized FCF $20.8M · quality 44.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 32/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

58/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 16Warnings: 0unknown: 16
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · NUTXLocal privado en este navegador · Nutex Health Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$881M

P/E

9.4x

↓

EV/EBITDA

3.6x

↓

ROE

21.5%

↑

Gross Margin

50.8%

↑

Debt/Equity

1.07

↑
52-Week Range$128
$77$193

TradingView lightweight chart

NUTX price, volumen y niveles de valoración

Último $128.02Periodo -97.9%
Fair value: $128.02

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2010–2025 · 15 años de histórico normalizado

Revenue CAGR

+58.5%

FCF CAGR

—

FCF margin

28.1%

FCF / Net income

3.47x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $875.3M · net income $70.8M · FCF $245.6M

2010-FY → 2025-FY

Gross margin

50.8%-4.5% pts

Operating margin

31.5%+185.4% pts

Net margin

8.1%-10.0% pts

FCF margin

28.1%+214.6% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Income Statement
Revenue$875.3M$875.3M$479.9M$247.6M$219.3M$331.5M$274.0M$1.4M$1.4M$23166.00$0.00$474679.00$1.1M$1.5M$1.6M$1.8M$874774.00
Net Income$70.8M$70.8M$52.1M$-45.8M$-424.8M$132.6M$106.0M$-7.1M$-950129.00$582062.00$-7.4M$83809.00$-684342.00$250489.00$-1.6M$-383393.00$158137.00
EBITDA$287.5M$287.5M$148.7M$-14.6M$-394.0M$177.9M$159.1M$-6.7M$-837713.00———$-660182.00$-687131.00———
EPS10.4810.489.71-10.50-100.5033.0027.00——————————
Gross Margin50.8%50.8%40.9%14.0%7.0%54.1%57.5%39.2%62.9%-31.6%—98.3%56.5%66.1%50.8%57.1%55.2%
Operating Margin31.5%31.5%28.7%-0.6%-2.1%51.4%55.9%-504.8%-61.5%-24574.5%—-112.3%-67.7%-49.8%-98.7%-47.3%-153.9%
Net Margin8.1%8.1%10.9%-18.5%-193.7%40.0%38.7%-520.8%-69.5%2512.6%—17.7%-64.0%17.1%-101.9%-21.5%18.1%
Balance Sheet
Debt/Equity1.071.072.574.492.790.690.000.00-0.20————————
Current Ratio3.143.14———————————————
Cash Flow
Free Cash Flow$245.6M$245.6M$20.8M$-8.2M$36.0M$136.5M$25.5M$-4.1M$-480049.00——$46704.00$161228.00—$-510630.00$-639745.00$-1.6M
Returns
ROE21.5%21.5%39.3%-74.5%-443.1%115.6%-9346.5%-382.9%63.5%-58.4%126.6%5.4%—————
Valuation
P/E9.379.373.49——————————————
EV/EBITDA3.583.583.24——————————————
P/B2.632.631.372.2411.51————————————
Growth & Yield
Revenue Growth82.4%82.4%93.8%12.9%—21.0%19954.5%-0.0%5800.9%—-100.0%-55.6%-26.9%-8.3%-10.7%103.9%—
EPS Growth7.9%7.9%192.5%89.6%—22.2%———————————

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

2.7%

fácil

EPS terminal req.

$11.36

Spread vs growth

5.2%

5Y implied EPS CAGR

5.6%

razonable

EPS terminal req.

$13.75

Spread vs growth

2.4%

10Y implied EPS CAGR

7.8%

razonable

EPS terminal req.

$22.14

Spread vs growth

0.2%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -23.7%

Total return

-23.7%

Start / end P/E

17.3x → 12.2x

EPS bridge

9.71 → 10.48

Residual

-2.3%

EPS growth+7.9%
Multiple rerating-29.3%
Dividend+0.0%
Residual / FX / buybacks / cross-term-2.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.